# Seawolf Therapeutics

> Preclinical biotech developing redosable lipid-nanoparticle DNA medicines with its TRIDENT nuclear-delivery platform.

## Why it is interesting

Issuer announced $100M accumulated across Seed and Series A on November 16, 2026, not $100M independently confirmed as a Series A alone. Its separate Sanofi R&D/license deal has up to $1.2B contingent milestones; no guaranteed upfront proceeds or clinical approval disclosed.

## Profile

- **Latest funding:** Seed plus Series A, aggregate previously raised; split amounts undisclosed — $100M combined (November 16, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $100M
- **Stage:** series-a
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-11-17
- **Latest funding investors:** Versant Ventures, MPM BioImpact, Novartis Venture Fund, Eli Lilly and Company, CRISPR Therapeutics, Sixty Degree Capital, Alexandria Venture Investments, Pathway to Cures

## Key facts

- $100M aggregate across distinct Versant-led Seed and later Series A; allocations, legal close dates and valuation undisclosed.
- Founding investor Versant led Seed; Series A involved Versant, MPM BioImpact, Novartis Venture Fund, Eli Lilly, CRISPR Therapeutics, Sixty Degree Capital, Alexandria and Pathway to Cures.
- Separate multi-target Sanofi agreement can pay up to $1.2B in contingent research/development/commercial milestones plus royalties; upfront not disclosed. Do not count as equity or cash realized.
- TRIDENT LNP nuclear DNA delivery has only company-reported preclinical primate/mouse data; no approved treatment, commercial pricing or reported drug revenue.

## Funding history

- Seed plus Series A, aggregate previously raised; split amounts undisclosed · $100M combined · November 16, 2026
  Source: https://www.businesswire.com/news/home/20261116723769/en/

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 17, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/seawolf-therapeutics
